Evogene (EVGN) Reports Q3 Loss of $0.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Evogene Reports Third Quarter 2017 Financial Results
November 22, 2017 7:00 AM ESTREHOVOT, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today its financial results for the third quarter ending September 30, 2017.
Ofer Haviv, Evogene's President and CEO, stated: This is an exciting time for Evogene, as we rapidly advance the evolution of our company from a plant genomics company to a company addressing a wide... More
